Cardioprotective and other emerging effects of statins

International Journal of Clinical Practice, Supplement

Volumn , Issue 143, 2004, Pages 49-57

  Davignon, Jean ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Atherosclerosis; Cardioprotection; Coronary artery disease; Inflammation; Pleiotropic effects; Statins

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ATORVASTATIN; CD40 ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; PRAVASTATIN; PROSTAGLANDIN SYNTHASE; ROSUVASTATIN; STATINE DERIVATIVE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; HEART PROTECTION; HUMAN; IMMUNOMODULATION; LIPID METABOLISM; OUTCOMES RESEARCH; PRIORITY JOURNAL;

ANTI-INFLAMMATORY AGENTS; ANTILIPEMIC AGENTS; ANTIOXIDANTS; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 10344262021     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (99)

1. Neaton JD, Blackburn H, Jacobs D, et al., the Multiple Risk Factor Intervention Trial Research Group. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch Intern Med 1992; 152: 1490-500.
2. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256: 2823-8.
3. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA 1987; 257: 2176-80.
4. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/Tex-CAPS. JAMA 1998; 279: 1615-22.
5. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
6. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994; 344: 1383-9.
7. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia: West of Scotland Coronary Prevention Group. N Engl J Med 1995; 339: 1301-7.
8. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: the long-term intervention with pravastatin in ischaemic disease (LIPID) study. N Engl J Med 1998; 339: 1349-57.
9. Heart Protection Study Collaborative Group. The MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
10. Packard CJ. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97: 1440-5.
11. Davignon J, Laaksonen R. Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol 1999; 10: 543-59.
12. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109 (23 Suppl. 1): III39-43.
13. Bellosta S, Ferri N, Arnaboldi L, et al. Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes Care 2000; 23 (Suppl. 2): B72-8.
14. Laufs U, Liao JK. Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med 2000; 10: 143-8.
15. LaRosa JC. Pleiotropic effects of statins and their clinical significance. Am J Cardiol 2001; 88: 291-3.
16. Lefer AM, Scalia R, Lefer DJ. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res 2001; 49: 281-7.
17. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002; 110: 285-8.
18. Laine P, Pentikainen MO, Wurzner R, et al. Evidence for complement activation in ruptured coronary plaques in acute myocardial infarction. Am J Cardiol 2002; 90: 404-8.
19. Mason JC, Ahmed Z, Mankoff R, et al. Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury. Circ Res 2002; 91: 696-703.
20. Franzoni F, Quinones-Galvan A, Regoli F, et al. A comparative study of the in vitro antioxidant activity of statins. Int J Cardiol 2003; 90: 317-21.
21. De Caterina R, Cipollone F, Filardo FP, et al. Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-A inhibitor simvastatin is accompanied by a related reduction of F2-isoprostane formation in hypercholesterolemic subjects - No further effect of vitamin E. Circulation 2002; 106: 2543-9.
22. Shishehbor MH, Aviles RJ, Brennan ML, et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 2003; 289: 1675-80.
23. Shishehbor MH, Brennan ML, Aviles RJ, et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 2003; 108: 426-31.
24. Libby P, Sukhova G, Lee RT, Liao JK. Molecular biology of atherosclerosis. Int J Cardiol 1997; 62 (Suppl. 2): S23-S29.
25. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction-a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23: 168-75.
26. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126-31.
27. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332: 481-7.
28. Nangle MR, Cotter MA, Cameron NE. Effects of rosuvastatin on nitric oxide-dependent function in aorta and corpus cavernosum of diabetic mice: relationship to cholesterol biosynthesis pathway inhibition and lipid lowering. Diabetes 2003; 52: 2396-402.
29. Davignon J, Jacob F, Mason RP. The antioxidant effects of statins. Coron Artery Dis 2004; 15: 251-8.
30. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation 2004; 109 (21 Suppl. 1): 1127-33.
31. Jones SP, Gibson MF, Rimmer DM 3rd, et al. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol 2002; 40: 1172-8.
32. Cayatte AJ, Palacino JJ, Horten K, Cohen RA. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arteriosder Thromb 1994; 14: 753-9.
33. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-35.
34. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998; 273: 24266-71.
35. Feron O, Dessy C, Moniotte S, et al. Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J Clin Invest 1999; 103: 897-905.
36. Brouet A, Sonveaux P, Dessy C, et al. Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res 2001; 89: 866-73.
37. Feron O, Dessy C, Desager JP, Balligand JL. Hydroxy-methylglutaryl- coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001; 103: 113-8.
38. Pelat M, Dessy C, Massion P, et al. Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E (-/-) mice in vivo. Circulation 2003; 107: 2480-6.
39. Hattori Y, Nakanishi N, Akimoto K, et al. HMG-CoA reductase inhibitor increases GTP cyclohydrolase I mRNA and tetrahydrobiopterin in vascular endothelial cells. Arteriosder Thromb Vasc Biol 2003; 23: 176-82.
40. Shinozaki K, Kashiwagi A, Masada M, Okamura T. Molecular mechanisms of impaired endothelial function associated with insulin resistance. Curr Drug Targets Cardiovasc Haematol Disord 2004; 4: 1-11.
41. Spieker LE, Noll G, Luscher TF. Therapeutic potential for endothelin receptor antagonists in cardiovascular disorders. Am J Cardiovasc Drugs 2001; 1: 293-303.
42. Glorioso N, Troffa C, Filigheddu F, et al. Effect of the HMGCoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999; 34: 1281-6.
43. Nakamura T, Ushiyama C, Hirokawa K, et al. Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with micro-albuminuria and dyslipidemia. Am J Nephrol 2001; 21: 449-54.
44. Sánchez-Quesada JL, Otal-Entraigas C, Franco M, et al. Effect of simvastatin treatment on the electronegative low-density lipoprotein present in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 1999; 84: 655-9.
45. Pruefer D, Scalia R, Lefer AM. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler Thromb Vasc Biol 1999; 19: 2894-900.
46. Stalker TJ, Lefer AM, Scalia R. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br J Pharmacol 2001; 133: 406-12.
47. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Stalins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7: 687-92.
48. Nawawi H, Osman NS, Yusoff K, Khalid BA. Reduction in serum levels of adhesion molecules, interleukin-6 and C-reactive protein following short-term low-dose atorvastatin treatment in patients with non-familial hypercholesterolemia. Horm Metab Res 2003; 35: 479-85.
49. Dupuis J. Mechanisms of acute coronary syndromes and the potential role of statins. Atheroscler Suppl 2001; 2: 9-14.
50. Fuster V, Stein B, Ambrose JA, et al. Atherosclerotic plaque rupture and thrombosis. Evolving concepts. Circulation 1990; 82 (Suppl. II): 47-59.
51. Davies MJ. Acute coronary thrombosis - the role of plaque disruption and its initiation and prevention. Eur Heart J 1995; 16 (Suppl. L): 3-7.
52. Moreno PR, Falk E, Palacios IF, et al. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 1994; 90: 775-8.
53. Henney AM, Wakeley PR, Davies MJ, et al. Location of stromelysin gene expression in atherosclerotic plaques by in situ hybridisation. Proc Natl Acad Sci USA 1991; 88: 8154-8.
54. Shah PK, Falk E, Badimon JJ, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995; 92: 1565-9.
55. Crisby M, Nordin-Fredriksson G, Shah PK, et al. Pravastatin treatment increases collagen content, decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001; 103: 926-33.
56. Cipollone F, Fazia M, Iezzi A, et al. Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation 2003; 107: 1479-85.
57. Aikawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001; 103: 276-83.
58. Furman C, Copin C, Kandoussi M, et al. Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability. Atherosclerosis 2004; 174: 93-8.
59. Luan ZX, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1,-2,-3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 2003; 23: 769-75.
60. Lusis AJ. Atherosclerosis. Nature 2000; 407: 233-41.
61. Nishi K, Itabe H, Uno M, et al. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol 2002; 22: 1649-54.
62. Giroux LM, Davignon J, Naruszewicz M. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim Biophys Acta 1993; 1165: 335-8.
63. Dtaude G, Hrboticky N, Lorenz RL. The expression of the lectin-like oxidized low-density lipoprotein receptor (LOX-1) on human vascular smooth muscle cells and monocytes and its down-regulation by lovastatin. Biochem Pharmacol 1999; 57: 383-6.
64. Pietsch A, Erl W, Lorenz RL. Lovastatin reduces expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells. Biochem Pharmacol 1996; 52: 433-9.
65. Fuhrman B, Koren L, Volkova N, et al. Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes. Atherosclerosis 2002; 164: 179-85.
66. Sasaki S, Kuwahara N, Kunitomo K, et al. Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia. Am J Cardiol 2002; 89: 386-9.
67. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994; 15: 74-80.
68. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-9.
69. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
70. Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731-3.
71. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998; 98: 839-44.
72. Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 2004; 109: 1955-9.
73. Prasad A, Zhu J, Halcox JP, et al. Predisposition to atherosclerosis by infections: role of endothelial dysfunction. Circulation 2002; 106: 184-90.
74. Ridker PM, Rifai N, Pfeffer MA, et al. Long term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999; 100: 230-5.
75. Ridker PM, Miles JS, Downs JR, et al. Lovastatin 20-40 mg/day lowers high sensitivity C-reactive protein levels in AFCAPS/TexCAPS. Circulation 2000; 102 (Suppl.): II833.
76. Ridker PM, Rifai N, Pitman Lowenthal S. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001; 103: 1191-3.
77. Kleemann R, Verschuren L, de Rooij BJ, et al. Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 2004; 103: 4188-94.
78. Hernandez-Presa MA, Ortego M, Tunon J, et al. Simvastatin reduces NF-kappaB activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet. Cardiovasc Res 2003; 57: 168-77.
79. Waehre T, Damas JK, Gullestad L, et al. Hydroxymelhylglylaryl coenzyme A reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. J Am Coll Cardiol 2003; 41: 1460-7.
80. Xu ZM, Zhao SP, Li QZ, et al. Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome. Clin Chim Acta 2003; 338: 17-24.
81. Stanislaus R, Gilg AG, Singh AK, Singh I. Immunomodulation of experimental autoimmune encephalomyelitis in the Lewis rats by lovastatin. Neurosci Lett 2002; 333: 167-70.
82. Youssef S, Stuve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420: 78-84.
83. Hakamada-Taguchi R, Uehara Y, Kuribayashi K, et al. Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ Res 2003; 93: 948-56.
84. Leung BP, Sattar N, Crilly A, et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003; 170: 1524-30.
85. Meroni PL, Raschi E, Testoni C, et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and pro-inflammatory phenotype. Arthritis Rheum 2001; 44: 2870-8.
86. Schönbeck U, Gerdes N, Varo N, et al. Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation 2002; 106: 2888-93.
87. Mulhaupt F, Matter CM, Kwak BR, et al. Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc Res 2003; 59: 755-66.
88. Schönbeck U, Libby P. CD40 signaling and plaque instability. Circ Res 2001; 89: 1092-103.
89. Lutgens E, Daemen MJ. CD40-CD40L interactions in atherosclerosis. Trends Cardiovasc Med 2002; 12: 27-32.
90. O'Sullivan B, Thomas R. CD40 and dendritic cell function. Crit Rev Immunol 2003; 23: 83-107.
91. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621-7.
92. Antonini-Canterin F, Zuppiroli A, Popescu BA, et al. Effect of statins on the progression of bioprosthetic aortic valve degeneration. Am J Cardiol 2003; 92: 1479-82.
93. Schaefer K, Kaiser K, Pynn M, Goeschen C, Konstantinides S. Effects of rosuvastatin on arterial thrombosis and atherosclerosis progression: Insights from an in vivo model of arterial injury in the apolipoprotein E-knockout mouse. Arterioscler Thromb Vasc Biol 2003; 23: a36-37 (Abstract P205).
94. Corti R, Fayad ZA, Fuster V, et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 2001; 104: 249-52.
95. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291: 1071-80.
96. Taylor AJ, Kent SM, Flaherty PJ, et al. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002; 106: 2055-60.
97. Nissen S. Design and methodology of a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden: the ASTEROID study. Atheroscler Suppl 2003; 4 (2): 27 (Abstract).
98. Grouse JR III, Grobbee DE, O'Leary DH, et al. Measuring effects on intima media thickness: an evaluation of rosuvastatin in subclinical atherosclerosis - The rationale and methodology of the METEOR Study. Cardiovasc Drugs Ther 2004; 18: 231-8.
99. Hatsukami TS, Zhao XQ, Yuan C, et al. Study design for a randomized, double-blind trial to assess the effect of 24 months of dosing with rosuvastatin on progression of carotid artery atheroma in moderately hypercholesterolemic patients with asymptomatic carotid stenosis. Atheroscler Suppl 2001; 2 (2): 47-8 (Abstract).